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ABSTRACT

The presently-disclosed subject matter includes methods for
treating Alzheimer's disease in a Subject. The Subject can
have Alzheimer's diseases, can be identified has being at risk
for developing Alzheimer's disease, or both. The method can
comprise administering a composition that includes a CD33
inhibitor, which may include a CD33 antibody. In some
embodiments the composition can further comprise at least
one additional component useful for treating Alzheimer's
disease. The presently-disclosed Subject matter also includes
compositions and kits for treating Alzheimer's disease in a
Subject.
6 Claims, 9 Drawing Sheets
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1.
METHOD, COMPOSITION, AND KIT USEFUL
FORTREATMENT OF ALZHEMERS
DISEASE
RELATED APPLICATIONS

This application claims priority from U.S. Provisional
Patent Application No. 61/733,126, filed Dec. 4, 2012, the
entire disclosure of which is incorporated herein by this ref
CCC.
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lm.

GOVERNMENT SUPPORT

FIG.2 includes charts of CD33 isoform expression relative
to Alzheimer's disease status, showing (A) CD33 expression
correlated with microglial gene expression (presented as geo

This invention was made with government Support under
Grant Nos. P01-AG03.0128, P30-AG028383, and P20

GM103436 awarded by the National Institutes of Health. The
government has certain rights in the invention.

2
(arrows) that have a morphology consistent with microglia in
both Alzheimer's disease (AD) and non-AD samples (A, B);
and also includes immunofluorescence images used to help
distinguish CD33-immunopositive cell types, where (C-H)
show the same microscope fields and show sections immun
ostained for CD33 and counterstained for IBA-1 (a micro
glial/macrophage lineage marker) or GFAP (an astrocyte lin
eage marker). Sections were from Superior/middle temporal
gyri of subjects with AD pathology (A, C-H) or without (B)
AD pathology. Ctrl, Control. Scale bar: a, b, 50 um; c-h, 20

15

metric mean of CD11b and AIF-1, r=0.64), (B) association
between CD33 and Alzheimer's disease status visualized by
considering the ratio of CD33 to the geometric mean of the
microglial reference genes, (C) D2-CD33 correlated with

TECHNICAL FIELD

CD33 expression (r=0.88, 0.67, and 0.51 for the AA, CA,

The presently-disclosed subject matter relates to the treat
ment of a subject having or identified as being at risk for
developing Alzheimer's disease. In particular, the presently
disclosed subject matter relates to methods and compositions
for treating Alzheimer's disease by reducing functional CD33
in a Subject.

and CC genotypes, respectively), and (D) the percentage of
CD33 expressed as D2-CD33 associated with the rs3865444

genotype (p=1.2x10').

25

FIG. 3 includes a schematic showing the mechanisms for
CD33 and TREM2 in microglial activation, where sialic acid
binding to CD33 results in activation of SHP1 phosphatase
that inhibits immune cell activation, the D2-CD33 isoform

INTRODUCTION

Recent genome-wide association studies (GWASs) have
identified a set of single nucleotide polymorphisms (SNPs)
that are associated with Alzheimer's disease (AD) risk. One
of the AD-associated SNPs, rs3865444, is in the proximal
promoter of CD33. CD33 is a member of the sialic acid
binding Ig-like lectin (SIGLEC) family of receptors
However, there has been limited progress in elucidating the
mechanisms of action underlying such SNPs. This difficulty
can be attributed to variability in human gene expression due
to diversity in genetics and environment, including diet and
drug exposure. The difficulty can also be attributed to the fact
that the brain contains heterogeneous cell types, and control
ling for variation in the proportion of cell types between
samples is challenging. Lastly, AD-associated SNPs from
GWAS are not typically functional, but rather are in linkage
disequilibrium (LD) with functional SNP(s), which intro
duces variability.
Elucidating the mechanism of action of these SNPs could
potentially be beneficial for identifying novel Alzheimer's
disease pathways. Indeed, genetic variation that modulates
disease risk could be considered to biologically define rate
limiting steps in Alzheimer's disease pathways, and, as such,
lead to robust new pharmacologic targets. For example, an
SNP with modest biological actions may reduce Alzheimer's
disease risk modestly, whereas a drug that acts strongly at the
same target may have a large effect on Alzheimer's disease
risk reduction. Elucidating the mechanism of action of AD
associated SNP may therefore lead to the development of

30

CD33.
35

40

FIG. 5 includes charts of Int1-CD33 expression relative to
Alzheimer's disease status, showing (A) Int1-CD33 expres
sion correlated with CD33 expression, (B) the percentage of
CD33 expressed as Int1-CD33 associated with the rs3865444
genotype, (C) total non-functional CD33 correlated with
CD33 expression, and (D) the percentage of CD33 expressed
as non-functional CD33 associated with the rs3865444 geno

type.

DESCRIPTION OF EXEMPLARY
EMBODIMENTS
45

The details of one or more embodiments of the presently
disclosed subject matter are set forth in this document. Modi
fications to embodiments described in this document, and

50
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treatments for Alzheimer's disease.

Hence, there remains a need to elucidate the mechanism of
action of AD-associated SNPs. There also remains a need to

develop novel compositions and methods for treating Alzhe

lacks the exon that encodes the apparent sialic acid binding
domain, and a ligand binds TREM2 that signals through
DAP12 to activate the tyrosine kinase Syk, resulting in micro
glial activation.
FIG. 4 includes a schematic showing the gene structure for

60

other embodiments, will be evident to those of ordinary skill
in the art after a study of the information provided in this
document. The information provided in this document, and
particularly the specific details of the described exemplary
embodiments, is provided primarily for clearness of under
standing and no unnecessary limitations are to be understood
therefrom. In case of conflict, the specification of this docu
ment, including definitions, will control.
Some of the polynucleotides and polypeptides identified
herein include sequence and other information in the GEN
BANKR/GENPEPTOR database, which sequence and other
information is expressly incorporated by reference. Unless
otherwise indicated or apparent, the references to the GEN

imer's disease that are based on information elucidated form

BANKOR/GENPEPTOR) database are references to the most

particular AD-associated SNPs.

recent version of the database as of the filing date of this
Application.
The presently-disclosed subject matter includes methods,
compositions, and kits useful for the treatment of Alzheimer's
disease (AD) in a Subject. In some embodiment, the Subject
has Alzheimer's disease. In some embodiments, the Subject is

BRIEF DESCRIPTION OF THE DRAWINGS
65

FIG. 1 includes CD33 immunohistochemistry images in
human brain showing CD33-immunopositive cell profiles
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3
identified as being at risk for developing Alzheimer's disease.

4
functional CD33 and/or by reducing a ratio of functional

As such, treatment of Alzheimer's disease is not limited to

CD33 to nonfunctional CD33.

treatment of subjects who have already been diagnosed with

As used herein, the terms “treatment' or “treating are
inclusive of prophylactic treatment and therapeutic treatment.
As such, the terms treatment and treating include: preventing
the disease from occurring in a Subject who may be predis
posed to the disease but who has not yet been diagnosed as
having it; inhibiting the disease, including arresting the pro
gression or development of the disease; reducing the severity
of the disease; ameliorating or relieving the symptoms of the
disease; causing regression of disease; curing the disease;
and/or stabilizing the disease. This term includes active treat
ment, that is, treatment directed specifically toward the
improvement of a disease, pathological condition, or disor

Alzheimer's disease, but is inclusive of the treatment of sub

jects who are identified as having an increased risk of Alzhe
imer's disease as compared to the general population. The
phrase “increased risk” is used herein to refer to those sub
jects whose likelihood of developinga Alzheimer's disease in
their lifetime is increased, as compared to a normal Subject.
Furthermore, the Subject can be a human Subject or a non
human Subject.
In some embodiments, the Subject is identified has having
a single nucleotide polymorphism associated with risk of
developing Alzheimer's disease. In this regard, certain
mechanisms identified by these SNPs constitute “bottle
necks' in Alzheimer's disease pathways. These bottlenecks
can biologically define rate-limiting steps in Alzheimer's dis
ease pathways, and, as such, can constitute targets for treat
ment. For example, a SNP may reduce Alzheimer's disease
risk modestly (e.g., 10%), but a drug that acts strongly at the
same target may have a more robust (e.g., 10-50%) effect on
Alzheimer's disease risk and gene function.
In some embodiments, the SNP is the CD33 polymor
phism, rs3865444, rs3865444 (rs444), a SNP near CD33,
appears to be AD-associated, as shown in cohorts totaling

10

15

ease, pathological condition, or disorder. In addition, this
term includes preventative treatment, that is, treatment
directed to minimizing or partially or completely inhibiting
the development of the associated disease, pathological con
dition, or disorder.

25

more than 48,000 individuals (odds ratio=0.89, p=10). The

present inventors identified the effect of rS444 on CD33 as
well as different CD33 isoforms expressed in human brain. In
certain subjects, a CD33 isoform containing all seven CD33
exons can be relatively common, as can be nonfunctional
CD33 isoforms, such as those lacking exon 2 (D2-CD33) or
those retaining intron 1 (Int1-CD33).
Thus, the present-disclosed subject matter provides an
understanding of how Alzheimer's disease risk can be modu
lated by genetic factors that influence microglial activation.

30

35

skilled in the art and include, but are not limited to, oral
administration, transdermal administration, administration
intraaural administration, intracerebral administration, rectal

40

administration, and parenteral administration, including
injectable Such as intravenous administration, intra-arterial
administration, intramuscular administration, Subcutaneous
administration, intravitreous administration, intracameral

45

(into anterior chamber) administration, Subretinal adminis
tration, Sub-Tenon's administration, peribulbar administra
tion, administration via topical eye drops, and the like.
Administration can be continuous or intermittent. In various

50

aspects, a preparation can be administered therapeutically;
that is, administered to treat an existing disease or condition
(e.g., exposure to OP compounds). In further various aspects,
a preparation can be administered prophylactically; that is,
administered for prevention of a disease or condition.
In some embodiments, the composition administered can
include a CD33 inhibitor. The CD33 inhibitor can be selected,

55

for example, from a polypeptide inhibitor (including oligo
nucleotide inhibitor), a small molecule inhibitor, an siRNA
inhibitor, an antibody, an aptamer, a dominant negative plas
mid or vector inhibitor, and combinations thereof.

ease risk.

Thus, the presently-disclosed subject matter relates to pro

rs3865444, rs12459419, or combinations thereof.

by inhalation, nasal administration, topical administration,
intravaginal administration, ophthalmic administration,

found to be inhibited when BV2 cells are transfected with

CD33, but not CD33 lacking the IgV domain. Hence,
D2-CD33 likely represents a loss of CD33 function. There
fore, it appears that TREM2 and CD33 act in opposing direc
tions to modulate tyrosine phosphorylation and, thereby,
microglial activation and AD risk. Alleles that inhibit TREM2
function may increase Alzheimer's disease risk, whereas alle
les that inhibit CD33 function may reduce Alzheimer's dis

In some embodiments, the method includes administering
a composition for reducing functional CD33 in the subject,
wherein the subject has Alzheimer's disease or is identified as
being at risk for developing Alzheimer's disease. In some
embodiments, the method includes administering a compo
sition for reducing functional CD33 in the subject, wherein
the Subject is identified as having a single nucleotide poly
morphism associated with risk of Alzheimer's disease, e.g.,
The term “administering” refers to any method of provid
ing a composition and/or pharmaceutical composition
thereof to a subject. Such methods are well known to those

Increased Alzheimer's disease risk has been associated with

apparent inactivating mutations in the microglial activator
TREM2, and TREM2 acts via DAP12 to activate Syk medi
ated tyrosine phosphorylation to promote microglial phago
cytosis (FIG. 3). The present inventors found that
rs3865444A is associated with lower overall CD33 expres
sion as well as exclusion of CD33 exon 2 and possibly other
nonfunctional CD33 (e.g., Int1-CD33).
In this regard, sialic acids activate CD33 to stimulate
SHP1/SHP2 tyrosine phosphatases, resulting in inhibition of
phagocytosis (FIG. 3). Because D2-CD33 lacks the IgV
domain that is predicted to mediate sialic acid binding,
D2-CD33 likely encodes a nonfunctional protein. Consistent
with this, phagocytosis as measured by AB uptake has been

der, and also includes causal treatment, that is, treatment
directed toward removal of the cause of the associated dis

60

In this regard, the term “inhibit or the like does not nec
essarily refer to the ability to completely inactivate all target
biological activity in all cases. Rather, the skilled artisan will

tective SNP alleles as well as Alzheimer's disease treatment

understand that the term “inhibit” refers to a decrease bio

methods and compositions that are based on the same. In
certain subjects the AD-protectivers444A allele is associated
with an about 10% per allele increase in the expression of
CD33 lacking exon 2 (D2-CD33). Certain embodiments of
the presently-disclosed subject matter relate to methods and
compositions for treating Alzheimer's disease by reducing

logical activity of a target, such as a decreasing expression of
CD33 and/or functional CD33. This can occur by various
mechanisms, including, but not limited to, altering the struc
ture of a protein so that its intended function is limited or
eliminated in in a biochemical pathway, blocking particular
binding sites in a biological pathway, or the like. Such

65
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5
decrease in biological activity (i.e., inhibition) can be deter
mined relative to a control, wherein an inhibitor is not admin

istered and/or placed in contact with the target. For example,
in some embodiments, a decrease in activity relative to a
control can be about a 1,2,3,4,5,6,7,8,9, 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,
32,33,34, 35,36, 37,38,39, 40, 41, 42, 43,44, 45,46, 47, 48,
49, 50, 51, 52,53,54, 55,56, 57,58, 59, 60, 61, 62,63, 64, 65,
66, 67,68, 69,70, 71, 72,73,74, 75,76, 77,78, 79,80, 81,82,
83, 84,85, 86, 87, 88, 89,90,91, 92,93, 94.95, 96, 97,98,99,

or 100% decrease. The term “inhibitor refers to a compound
of composition that inactivates or decreases the biological
activity, such as CD33 inhibitors that inactivate or decrease
the biological activity of CD33.
In specific embodiments the composition administered can
include a CD33 inhibitor that includes an antibody, wherein
the antibody is a CD33 antibody. A non-limiting example of
a CD33 antibody that could be used in connection with the
presently-disclosed subject matter is lintuZumab. Another
exemplary CD33 antibody can include P67.6. In some

5

10

15

embodiments the CD33 inhibitor can include two or more

6
azepines (e.g., Valium(R) (diazepam) or Ativan R (lorazepam))
and non-benzodiazepines (e.g., Buspar R (buspirone)).
In some embodiments, a method for treating Alzheimer's
disease in a subject is provided that comprises administering
a composition for reducing functional CD33, and further
comprises administering another treatment for Alzheimer's
disease. The subject can have and/or be identified as being at
risk for developing Alzheimer's disease. The other treatment
can include any of the compositions described herein. Exem
plary treatments for Alzheimer's disease can also include
hormone replacement therapy, sensory therapies, other thera
pies, such as coenzyme Q10, coral calcium, huperzine A, and
omega-3 fatty acids.
In some embodiments of the present methods, the admin
istered composition increases a ratio of nonfunctional CD33
to functional CD33 in the subject. In some embodiments the
compositions Sustain approximately the same level of func
tional CD33 and activate (i.e., increases the level of) nonfunc
tional CD33. In some embodiments the compositions reduce
a level of functional CD33 and sustain approximately the

different antibodies, some or all of which can be CD33 anti

same level of nonfunctional CD33. Further still, in some

bodies. In some embodiments wherein the subject is admin
istered a CD33 inhibitor, such as a CD33 antibody, the subject
is not being treated for a cancer.
Despite the various approaches, in some embodiments the
administered composition includes humanized monoclonal
antibodies against CD33, which have been developed for
treatment of acute myeloid leukemia (AML). Antibodies
(e.g., monoclonal antibodies targeting CD33) that can be used
in conjunction with the present compositions, methods, and
kits include “naked' antibodies, such as Lintuzumab, which
is merely an antibody. Alternatively or additionally, the pro
vided antibodies in certain embodiments can be conjugated to
another biologically active agent, Such as the conjugated
compound Gemtuzumab ozogamicin. Antibodies such as
“LintuZumab' show specificity and target engagement in the
periphery as well as a safety profile marked by minimal side
effects. As CD33 antagonists, CD33 antibodies including
Lintuzumab down-regulate CD33 from the cell surface in

embodiments the compositions both reduce a level of (i.e.,
inhibit) functional CD33 and activate nonfunctional CD33.
Nonfunctional CD33 refers to any CD33 that includes a
mutation that alters, inhibits, or otherwise compromises the
normal biological activity of CD33. This includes CD33 hav
ing one or more deleterious SNPs. Nonfunctional CD33 also
includes some fragments of functional CD33. Exemplary
nonfunctional CD33 includes CD33 lacking exon 2 (D2
CD33), CD33 retaining intron 1 (Int1-CD33), and the like.
Accordingly, in Some embodiments of the present methods
the compositions can increase a ratio of nonfunctional CD33.

25
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Vivo and in vitro. Hence, antibodies Such as LintuZumab

represent immunoreagents with specificity and peripheral
efficacy in target engagement, an acceptable safety profile,
and demonstrated ability to antagonize CD33.
In some embodiments, the method includes administering
a CD33 inhibitor, which can itself include a CD33 antibody,
and further includes administering a composition including at
least one component useful for treating Alzheimer's disease.
In some embodiments, the method includes administering a
composition including a CD33 inhibitor and/or a CD33 anti
body, and further including another component useful for
treating Alzheimer's disease. Examples of Such components
include, but are not limited to, Razadyne R (galantamine),
Exelon R (rivastigmine), Aricept(R) (donepezil), CognexcR)
(tacrine), and Namenda(R) (memantine). Exemplary compo
nents use for treating Alzheimer's disease also can include

45

50

ease. As described herein, the CD33 inhibitor can include a

polypeptide inhibitor, a small molecule inhibitor, an siRNA
inhibitor, an antibody, an aptamer, a dominant negative plas
mid or vector inhibitor, and combinations thereof. Further

more, the CD33 inhibitor can include a CD33 antibody, such
55

as lintuzumab, P67.7, or combinations thereof. Also as dis

cussed herein, the at least one additional component useful
for treating Alzheimer's disease can include, but is not limited
to, galantamine, rivastigmine, donepezil, tacrine, memantine,

vitamin E.

Further still, other exemplary components for treating
(e.g., ameliorating the symptoms of) Alzheimer's disease,
and which can be administer in conjunction with a CD33
inhibitor, include antidepressants, such as Celexa R. (citalo
pram), ProzacR) (fluoxetine), Paxil.R (paroxetine), and
Zoloft(R) (sertraline), anxiolytics, such as Ativan R.
(lorazepam) and SeraXR (oxazepam), antipsychotic medica
tions, such as Abilify(R) (aripiprazole), Haldol R (haloperidol),
ZyprexaR (olanzapine), clozapine, risperidone, quetiapine,
and Ziprasidone, anti-anxiety medications, such as benzodi

which can include D2-CD33, Int1-CD33, or combinations

thereof, to functional CD33 in the subject.
In some embodiments the subject that is being treated for
Alzheimer's disease is not being further treated for cancer.
Therefore, in some embodiments, the subject has not been
diagnosed as having cancer and/or has not been identified as
having a risk for developing cancer. In specific embodiments
the Subject does not have, has not been diagnosed as having,
and/or has not been identified as being at risk for developing
acute myeloid leukemia (AML). In this regard, in some
embodiments the present methods are performed only for the
purpose of treating Alzheimer's disease.
The presently-disclosed subject matter further includes a
composition comprising a CD33 inhibitor and at least one
additional component useful for treating Alzheimer's dis

Vitamin E, and combinations thereof.

60

Embodiments of the present compositions are capable of
increasing a ratio of nonfunctional CD33 to functional CD33
in a Subject. Alternatively or additionally, exemplary compo
sitions can also be capable of activating nonfunctional CD33
in a subject, such as, but not limited to, D2-CD33 and/or

65

Int1-CD33.

Additionally, the presently-disclosed subject matter
includes pharmaceutical compositions. Exemplary pharma

US 9,066,928 B1
7
ceutical compositions can comprise any of the compositions
described herein as well as a pharmaceutically acceptable
carrier.

The term “pharmaceutically acceptable carrier refers to
sterile aqueous or nonaqueous solutions, dispersions, Suspen
sions, emulsions, or nanoparticle delivery systems, as well as
sterile powders for reconstitution into sterile injectable solu
tions or dispersions just prior to use. Proper fluidity can be
maintained, for example, by the use of coating materials such
as lecithin, by the maintenance of the required particle size in
the case of dispersions and by the use of Surfactants. These
compositions can also contain adjuvants such as preserva
tives, wetting agents, emulsifying agents and dispersing
agents. Prevention of the action of microorganisms can be
ensured by the inclusion of various antibacterial and antifun
gal agents such as paraben, chlorobutanol, phenol, Sorbic acid
and the like. It can also be desirable to include isotonic agents
Such as Sugars, Sodium chloride and the like. Prolonged
absorption of the injectable pharmaceutical form can be
brought about by the inclusion of agents, such as aluminum
monostearate and gelatin, which delay absorption. Injectable
depot forms are made by forming microencapsule matrices of
the drug in biodegradable polymers such as polylactide
polyglycolide, poly(orthoesters) and poly(anhydrides).
Depending upon the ratio of drug to polymer and the nature of
the particular polymer employed, the rate of drug release can
be controlled. Depot injectable formulations are also pre
pared by entrapping the drug in liposomes or microemulsions
which are compatible with body tissues. The injectable for
mulations can be sterilized, for example, by filtration through
a bacterial-retaining filter or by incorporating sterilizing
agents in the form of sterile solid compositions which can be
dissolved or dispersed in sterile water or other sterile inject
able media just prior to use. Suitable inert carriers can include
Sugars such as lactose.
Suitable formulations include aqueous and non-aqueous
sterile injection Solutions that can contain antioxidants, buff

5

10

lated in conventional manner.
15

The presently-disclosed subject matter further includes a
kit comprising a CD33 inhibitor, and at least one additional
component useful for treating Alzheimer's disease. In some
embodiments the kit comprises a CD33 inhibitor that
includes an antibody, and at least one additional component
useful for treating Alzheimer's disease.
In some embodiments, kits can further include a device for

25

30

administering the CD33 inhibitor and/or a device for admin
istering the at least one additional component. The kit can
comprise one device for administering the CD33 inhibitor
and the additional component, or may comprise one device
for each of the CD33 inhibitor and the additional component.
The ordinary artisan will appreciate certain devices that can
be utilized in conjunction with the present kits. For instance,
injectable CD33 inhibitors, additional components, or both
can be administered by a device that includes, but is not
limited to, a syringe, a hypodermic needle, a catheter, or the
like.

35

ers, bacteriostats, bactericidal antibiotics and Solutes that ren

der the formulation isotonic with the bodily fluids of the
intended recipient; and aqueous and non-aqueous sterile Sus
pensions, which can include Suspending agents and thicken
ing agents.
The compositions can take Such forms as Suspensions,
Solutions or emulsions in oily or aqueous vehicles, and can
contain formulatory agents such as Suspending, stabilizing
and/or dispersing agents. Alternatively, the active ingredient
can be in powderform for constitution with a suitable vehicle,
e.g., sterile pyrogen-free water, before use.
The formulations can be presented in unit-dose or multi
dose containers, for example sealed ampoules and vials, and
can be stored in a frozen or freeze-dried (lyophilized) condi
tion requiring only the addition of sterile liquid carrier imme
diately prior to use.
For oral administration, the compositions can take the form
of for example, tablets or capsules prepared by a conven
tional technique with pharmaceutically acceptable excipients
Such as binding agents (e.g., pregelatinized maize starch,
polyvinylpyrrolidone or hydroxypropyl methylcellulose):
fillers (e.g., lactose, microcrystalline cellulose or calcium
hydrogen phosphate); lubricants (e.g., magnesium Stearate,
talc or silica); disintegrants (e.g., potato starch or sodium
starch glycollate); or wetting agents (e.g., sodium lauryl Sul
phate). The tablets can be coated by methods known in the art.
Liquid preparations for oral administration can take the
form of for example, Solutions, syrups or Suspensions, or
they can be presented as a dry product for constitution with
water or other suitable vehicle before use. Such liquid prepa

8
rations can be prepared by conventional techniques with
pharmaceutically acceptable additives Such as Suspending
agents (e.g., Sorbitol syrup, cellulose derivatives or hydroge
nated edible fats); emulsifying agents (e.g. lecithin or acacia);
non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alco
hol or fractionated vegetable oils); and preservatives (e.g.,
methyl or propyl-p-hydroxybenzoates or sorbic acid). The
preparations can also contain buffer salts, flavoring, coloring
and Sweetening agents as appropriate. Preparations for oral
administration can be suitably formulated to give controlled
release of the active compound. Forbuccal administration the
compositions can take the form of tablets or lozenges formu
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Further still, the presently-disclosed subject matter relates
to novel methods for elucidating the mechanism of particular
SNPs. In some embodiments the methods comprise analyz
ing quantitative gene expression as a function of splice vari
ants and/or of cell-type variation among biological samples,
Such as brain samples. By looking at quantitative gene expres
sion in this relative manner, previous difficulties associated
with characterizing the function of particular SNPs can be
avoided or minimized.

Such difficulties included the inability to evaluate the
effects of particular gene expression due to the inherent vari
ability in gene expression due to genetic and environmental
conditions. Difficulties also included the inability to control
the relatively types and concentrations of cells between dif
ferent biological samples, which can include heterogeneous
cell types. Thus, the present methods of analyzing quantita
tive gene expression as a function of splice variants and/or
analyzing quantitative gene expression as a function of cell
type variation among biological samples, can avoid certain
inherent and possibly ambiguous variations that were present
in previous methods.
In particular embodiments, as described herein, the present
methods include a combination of qPCR assays specific to
individual CD33 isoforms, controlling for microglial content
in Samples, and/or recognizing that the functional polymor
phism is linked with the Alzheimer's disease SNP (rs444).
This method allowed the present inventors to elucidate the
mechanism associated with various SNPs, including rS444.
This method can be extended to elucidate the mechanism
associated with other SNPs that are associated with Alzhe

imer's disease. The present methods can also be extended to
elucidate the mechanism associated with SNPs that are not
associated with Alzheimer's disease.
65

The presently-disclosed subject matter is further illustrated
by the following specific but non-limiting examples. Some of
the following examples are prophetic, notwithstanding the
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numerical values, results and/or data referred to and con

tained in the examples. Additionally, the following examples
may include compilations of data that are representative of
data gathered at various times during the course of develop
ment and experimentation related to the present invention.

5

EXAMPLES

Example 1
10

This Example describes procedures used to elucidate the
mechanisms of the AD risk allele, rs3865444, and CD33. In

particular, this Example demonstrates that CD33 expression
is primarily microglial, that CD33 expression is increased in
AD, and that the AD-protective rs3865444A allele acts via its
proxy, rs12459419T, to increase the proportion of CD33
(functional CD33) expressed as nonfunctional CD33 (e.g.,
D2-CD33). This Example thus identifies a novel mechanism
for the protective allele of CD33 as well as potential treat
ments that include CD33 modulation in subjects having and/
or at risk for developing AD.
De-identified human brain specimens were provided by the
University of Kentucky Alzheimer's Disease (AD) Center
Neuropathology Core (Lexington, Ky.). Samples were from
30 women (14 non-AD and 16 AD) and 25 men (13 non-AD
and 12 AD). AD and non-AD designations were by consensus
conference, with disease being defined based on dementia
and AD neuropathology, i.e., neuritic plaques and neurofibril
lary tangles. RNA and DNA were prepared from these
samples.
To perform CD33 immunostaining paraffin-embedded tis
sue sections were cut at 5um, followed by antigen retrieval in
citrate buffer, pH 6.0, using a pressure cooker (3 min). Sec
tions were immersed in 5% goat serum in Tris-buffered
saline, followed by an overnight incubation in anti-CD33
(clone PWS44; 1:100 dilution; Leica). After thorough rinsing
in Tris-buffered saline, sections were incubated in biotiny
lated secondary antibody for 1 h, rinsed, incubated in ABC
reagent (Vector Laboratories, Burlingame, Calif.) for 1 h,
developed in Nova Red chromagen (Vector Laboratories),
and counterstained with Mayer's hematoxylin. For immun
ofluorescence, sections were treated similarly. Sections were
then labeled with CD33 antibody (1:100), IBA-1 (rabbit poly
clonal, 1:1000; Wako Chemicals, Richmond, Va.), and/or
GFAP (rabbit polyclonal. 1:10,000; Dako, Carpinteria,
Calif.), rinsed, and detected with labeled secondary antibod
ies (antirabbit DyLight 488-labeled anti-rabbit, 1:500; Jack

D2-CD33, one to two clones had both exons 7A and 7B,
15
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son Laboratories, Bar Harbor, Me., or Texas Red labeled

anti-mouse, 1:500; Jackson Laboratories). Autofluorescence
eliminator reagent (Millipore BioScience Research Reagents,
Billerica, Mass.) was used to block autofluorescence.
To identify CD33 splice variants in human brain, screening
for CD33 splice variants was performed on a pool of four
cDNA samples representing AD and non-AD individuals and
varying rs3865444 genotypes. Nested PCR was used to
amplify CD33 exons 1-7A and exons 1-7B in separate reac
tions. An initial 20 cycles of PCR (Platinum Taq; Invitrogen,
Carlsbad, Calif.) was performed by using forward primer
5'-CTCAGACATGCCGC TGCT-3' (SEQ ID NO: 1) corre
sponding to exon 1 and reverse primers 5'-TTCAATGGC
CATCATCTCCT-3' (SEQ ID NO: 2) and 5'-CATCCCAT
GAAAGTTGAGGG-3 (SEQ ID NO:3), corresponding to
exons 7A and 7B, respectively. The PCR product was then
diluted 1:25 and subjected to 30 cycles of amplification using
forward primer 5'-TACTGCTGCCCCTGCTGT-3' (SEQ ID
NO: 4) from exon 1 and 5'-TGGCCATCATCTCCTGATCT
3' (SEQID NO:5) and 5'-AATGCAGCTCCTCATCCATC-3'

10
(SEQID NO: 6) corresponding to exons 7A and 7B, respec
tively. PCR consisted of an initial 3-min 94° incubation,
followed by cycles of denaturation at 94 for 15 s, annealing
at 60° for 15s, and extension at 72° for 2 min (Veriti 96-Well
Thermal Cycler: Invitrogen). PCR was conducted using 1 uM
the indicated primers (1 uM) and -0.1 g of cDNA template.
After PCR, samples were incubated at 72° for 30 min and then
cloned into pcDNA2.1 according to the instructions of the
manufacturer (TA-Cloning Kit; Invitrogen). Twenty-five ran
dom clones were picked from each group amplification reac
tion (exons 1-7A, exons 1-7B) and sequenced by using M13
forward and reverse primers. In addition to common
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skipped other exons, or retained intron 1 (Int1-CD33).
Quantitative PCR (qPCR) was used to quantify expression
of total CD33 (forward, 5'-TGTTCCACAGAACCCAA
CAA-3'(SEQ ID NO: 7); reverse, 5'-GGCTGTAACAC
CAGCTCCTC-3' (SEQID NO: 8)) primers corresponding to
sequences within exons 4 and 5, respectively. qPCT was also
used to quantify expression of total D2-CD33 (forward,
5'-CCCTGCTGTGGGCAGACTTG-3' (SEQ ID NO: 9);
reverse, 5'-GCACCGAGGAGTGAGTAGTCC-3'(SEQ ID
NO: 10)) primers corresponding to sequences at the exon 1-3
junction and exon 3, respectively. The specificity of the 1 to 3
junctional primer was confirmed by testing on CD33
sequence fragments containing or lacking exon 2, as well as
post-qPCR melting curve analysis and gel electrophoresis of
PCR products. PCR was conducted using an initial 2 min
incubation at 95°, followed by cycles of 10 sat 95°, 20s at
60°, and 20s at 72°. The 20 ul reactions contained 1 uM each
primer, 1X PerfecTa SYBR Green Super Mix (Quanta Bio
sciences, Gaithersburg, Md.), and 20 ng of cDNA. Experi
mental samples were amplified in parallel with serially
diluted standards that were generated by PCR of cDNA using
the indicated primers, followed by purification and quantita
tion by UV absorbance. Results from samples were compared
relative to the standard curve to calculate copy number in each
sample. Real-time assays were performed twice, and the aver
age copy number was used for additional data analyses.
To evaluate the correlation between CD33 and that of

microglial mRNAs, CD11b and AIF-1 expression was also
quantified. The copy number for each mRNA was then nor
malized to the geometric mean of reference genes RPL32 and
EIF4H, previously quantified in this sample set. Because
CD33 expression correlated with CD11b and AIF-1, total
CD33 expression was compared to the geometric mean of
CD11b and AIF-1 expression when analyzing CD33 expres
sion relative to AD status and rs3865444 genotype, correcting
for the microglial content of brain tissue samples from which
the cDNA was originally prepared. Expression of D2-CD33
was analyzed relative to total CD33 expression. To screen for
CD33 SNPs that may be tightly linked to rs3865444 and
modulate exon 2 splicing, seven individuals homozygous for
the major or minor allele of rs3865444 were sequenced from
400 bp 5' to the transcription start site through exon 4. Nested
PCR was conducted according to the directions of the manu
facturer (Phusion High-Fidelity DNA Polymerase: New
England Biolabs, Ipswich, Mass.); 20 PCR cycles were con
ducted with forward primer 5'-CTGTGCCCGAGCTGTCT
TAT-3'(SEQID NO: 11) and reverse primer 5'-AGGCTCCT
TCCTACCTGAGC-3' (SEQID NO: 12). PCR products were
then diluted 1:25 and used in a second round of PCR (25
cycles) using the forward primer 5'-GCTGCCACCT
TCACTTTACC-3' (SEQ ID NO: 13) with reverse primer
5'-TTGTTGGGTTCTGTGGAACA-3'(SEQ ID NO:14).
The first round of PCR used about 80 ng of genomic DNA
in a 20 ul reaction with both PCRs conducted using 3%
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DMSO. This process identified four SNPs in this region: (1)
rs3865444, the AD-associated promoter SNP; (2) rs2459 141,
which is 142 bp upstream of the transcription start site; (3)
rs 12459419 at the fourth base of exon 2; and (4) rs2455069 at

12
rs3865444A allele (FIGS. 2A and 2B). Similarly, regression

analysis showed a highly significant model (adjusted r°–0.76)
microglial gene expression (p=3.3x10', standardized B
coefficient of 0.78), AD status (p=5.9x10, standardized 0

wherein CD33 expression correlated significantly with

the 168th base of exon 2. rS12459419 was linked with

rs3865444 in these samples. Samples were subsequently
genotyped for rs12459419 by using a TaqMan approach (In
vitrogen); rs3865444 genotypes were determined by Ncol
restriction fragment length polymorphism.
CD33 minigenes containing exon 1 through exon 4 and
differential for rs12459419C/T were generated by PCR and
cloned into pcDNA3.1 (Invitrogen). Sequencing confirmed
that the inserts differed only at rs12459419C/T. BV2 micro
glial cells were maintained in DMEM/F-12 (Invitrogen)
supplemented with a final concentration of 10% fetal bovine
serum, 50 U/ml penicillin, and 50 lug/ml streptomycin. Cells

coefficient of 0.29), and rs3865444 genotype (p=0.012, stan
dardized B coefficient of -0.17). These results are consistent
with CD33 expression in microglia, increased CD33 expres
sion in AD, and decreased CD33 expression with the protec
10

15

were seeded in six-well plates (2x10 cells per well) and

allowed to grow for 24 h before transfection with 1 lug of
allele-specific CD33 minigene vector in 6 ul of Lipo
fectamine 2000 reagent (Invitrogen) and 94 IA of Opti-MEM,
per the recommendations of the manufacturer. Eighteenhours
after transfection, poly(A+)RNA was prepared and reverse
transcribed by using random hexamers per the directions of
the manufacturer (SuperScript III; Invitrogen). Three trans
fections were performed in duplicate for each allele. CD33
and D2-CD33 expression from the minigene was quantified
by qPCR using primers corresponding to exon 3-4 junction
and 3' vector-derived sequence (5'CAGCTCAACGTCAC
CTATGTTC (SEQ ID NO: 15) and 5'CGTAGAATC
GAGACCGAGGA (SEQ ID NO: 16)) and 5' vector and the
exon 1-3 junction (5"TGCTTACTGGCTTATCGAAATTA
(SEQID NO:17) and 5'TGTGGGTCAAGTCTGCCC (SEQ
ID NO: 18)), respectively. A one-tailed t test was used to
analyze the results.
Immunocytochemistry that localized CD33 expression in
human brain showed that CD33 expression in microglia, as
discerned by morphology (FIGS. 1A and 1B). Microglial
localization was confirmed by double labeling brain sections
for CD33 and IBA-1, a microglial protein, or GFAP, an astro
cytic protein (FIGS. 1C to 1F). Overall, predominant micro
glial localization is consistent with the potential role of CD33
as a sialic acid receptor that inhibits monocyte-lineage cell

25
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Because D2-CD33 was a common splice variant,
D2-CD33 was quantified by performing qPCR with primers
corresponding to the exon 1-3 junction and exon 3, as dis
cussed above. D2-CD33 expression was compared with total
CD33 expression, and isoform-specific standard curves were
analyzed in parallel with samples, which allowed absolute
quantitation of each isoform. D2-CD33 expression corre
sponded with CD33 expression and with rs3865444 genotype
(FIG. 2C). When D2-CD33 expression was considered as a
percentage of total CD33 expression, the association with
rs3865444 genotype was apparent (FIG. 2D). These findings
were confirmed by linear regression analyses, which found a

significant model (adjusted r=0.75) with D2-CD33 strongly
associated with rs3865444 genotype (p=1.01x10', stan
dardized f coefficient of 0.81), as well as CD33 expression
(p=2.3x10', standardized B coefficient of 0.58), and

decreased with AD status (p=0.013, standardized f coeffi
cient of -0.19). Hence, the proportion of CD33 expressed as
D2-CD33 showed a dose-dependent relationship with
rs3865444 allele. Indeed, in this Example the percentage of
CD33 expressed as D2-CD33 increased by 10.7+0.8% per
copy of the AD-protective rs3865444A allele.
Without being bound by theory or mechanism, since
rs3865444 resides in the CD33 promoter, and is therefore
unlikely to directly modulate exon 2 splicing, rs3865444 may
be coinherited with an SNP near or within exon 2 that modu

lates exon 2 splicing efficiency. To analyze this finding, CD33
from 400 bp 5% of the transcription start site through exon 4
was sequenced in four rs3865444C/C and three
40

rs3865444A/A individuals, as described above. Four SNPs

were observed in these samples: (1) rs3865444; (2)
rs2459 141 (142 bp upstream of the transcription start site);
(3) rs12459419 (the fourth base of exon 2); and (4) rs2455069
(the 168th base of exon 2). Among these variations, only

activation.

As discussed above, CD33 is encoded by seven exons,
including the alternatively spliced exons 7A and 7B (see, e.g.,
FIG. 4). Common CD33 isoforms in human brain were found
using PCR amplification on human brain cDNA using prim
ers corresponding to exon 1 and exon 7A or 7B. Sequencing
50 random clones revealed frequent isoforms lacking the 381
bp exon 2 (D2-CD33). Because the codon reading frame is

tive rs3865444A allele.

45

rs 12459419 was coinherited with rs3865444 in all seven indi

50

viduals (i.e., rs3865444AA individuals were also
rs 12459419TT), whereas rs3865444CC individuals were
rs 12459419CC. Subsequent rs12459419 genotyping of the
samples depicted in FIG. 2 found that rs12459419 major and
minor alleles were coinherited with rs3865444 major and

maintained in the absence of exon 2, D2-CD33 encodes a

minor alleles. Thus, the rs12459419C/Talleles substitute for

protein that is identical to CD33, but that lacks the IgV
domain that mediates sialic acid binding in SIGLEC family

the rs3865444C/A alleles in FIG. 2.

members. Both D2-CD33 and CD33 were found on the cell
surface of transfected cells.

Without being bound by theory or mechanism, rs3865444
modulates CD33 expression since this SNP is 372 bp
upstream of the CD33 transcription start site. To analyze this
finding. CD33 expression was assessed by performing qPCR
with primers corresponding to sequence within exons 4 and 5.
As described above, since immunostaining Suggested that
CD33 localized primarily to microglia, CD33 expression was
analyzed relative to the geometric mean of two microglial
mRNAs, CD11b and AIF-1 (IBA-1), as well as AD status and
rs3865444 genotype. It was observed that CD33 expression
correlated strongly with microglial mRNA expression, was
increased in AD, and was decreased with the AD-protective
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To evaluate whether rs12459419 is a functional polymor
phism and directly modulates exon 2 splicing efficiency,
CD33 minigenes for each rs12459419 allele were generated,
as discussed above. These minigenes included exon 1 through
exon 4, along with intervening introns, and the only differ
ence in minigene sequences was the rs12459419 alleles. This
analysis found that D2-CD33 as a percentage of total CD33
increased approximately threefold between cells transfected
with rs12459419C (3.4+1.4, mean+SE; n=3) versus
rs 12459419T minigenes (10.3+2.3, meant-SE; n=3,
p=0.034). These findings show that rs12459419 is a func
tional polymorphism and are consistent with the human brain
findings. In silico analysis of RNA binding proteins for the
RNA sequence containing rs12459419, GGG (C/U)CUG.
predicts that the splicing factor SRSF2 binds when
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rs 12459419C is present but not when rs124594149U is
present (scores of 4.1 and 1.4, respectively, threshold score
for binding of 2.4). SRSF2 is widely expressed, including
immune cells. It thus appears that rs12459419 mediates the
rs3865444 association with D2-CD33 expression in brain
becausers 12459419 is highly coinherited with rs3865444, is
the only SNP in exons 1-4 that is coinherited with rs3865444,
resides within exon 2, and has a plausible mechanism to
modulate splicing.
In summary, CD33 expression is increased in AD and in

14
numerical parameters set forthin this specification and claims
are approximations that can vary depending upon the desired
properties sought to be obtained by the presently-disclosed
Subject matter.
As used herein, the term “about, when referring to a value
or to an amount of mass, weight, time, Volume, concentration
or percentage is meant to encompass variations of in some
10

the specified amount, as Such variations are appropriate to
perform the disclosed method.
As used herein, ranges can be expressed as from “about
one particular value, and/or to “about another particular

individuals with the rs3865444Callele that is associated with

increased AD risk. Moreover, rs3865444 is associated with

CD33 exon 2 splicing efficiency through the exon 2 polymor
phism rs12459419, and rs12459419 may also be an appropri
ate polymorphism for developing AD treatments.
Example 2

15

disclosed herein, and that each value is also herein disclosed

This Example extends to the findings of Example 1, and

also disclosed. It is also understood that each unit between

two particular units are also disclosed. For example, if 10 and
15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

25

adjusted R=0.20) and with rs444 genotype (FIG. 5B,

p=0.004). The percentage of CD33 expressed as Int1-CD33
showed a dose-dependent relationship with rS444 allele,
increasing 2.3+0.8% per rS444A allele. Since D2-CD33 lacks
the ligand binding domain and Int1-CD33 has an early stop
codon, the amounts of D2-CD33 and Int1-CD33 were

30

1. Allen M, Zou F, Chai HS, Younkin CS, Crook J, Pankratz
35

rs444 (p=1x10') in a robust linear model (adjusted
R=0.657) (FIGS. 5C and 5D), with the percentage of CD33

expressed as non-functional-CD33 increasing 13.8+1.9% per
copy of AD-protectivers444A allele. It thus appears that there
was a significant 13.8% increase per protectivers444A allele
in CD33 encoding non-functional CD33 protein. Since

40

rs444A reduces the AD odds ratio to 0.9, more robust CD33

Unless defined otherwise, all technical and scientific terms

50

55

and materials are now described.

Following long-standing patent law convention, the terms
“a”, “an', and “the refer to “one or more' when used in this

application, including the claims. Thus, for example, refer
ence to “an antibody' includes a plurality of such antibodies,

60

and so forth.

Unless otherwise indicated, all numbers expressing quan
tities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about'. Accordingly, unless indicated to the contrary, the

79:221-228.

95-100.
45

stood by one of ordinary skill in the art, definitions are set
forth herein to facilitate explanation of the presently-dis
closed subject matter.
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which the presently
disclosed subject matter belongs. Although any methods,
devices, and materials similar or equivalent to those described
herein can be used in the practice or testing of the presently
disclosed subject matter, representative methods, devices,

VS, Carrasquillo MM, Rowley C N, Nair AA, Middha S,
Maharjan S, Nguyen T. Ma L., Malphrus KG, Palusak R.
Lincoln S. Bisceglio G, Georgescu. C. Schultz D. Rakhshan
F, et al. (2012) Novel late-onset Alzheimer disease loci
variants associate with brain gene expression. Neurology

2. Amadori, S. and R. Stasi, Integration of monoclonal anti
bodies and immunoconjugates into the treatment of acute
myeloid leukemia. Curr. Opin. Hematoll., 2008. 15(2): p.

inhibition may reduce AD more robustly. For example, a six
times stronger (i.e., about 84%) CD33 inhibition may reduce
AD odds ratio to 0.4.
While the terms used herein are believed to be well under

The presently-disclosed subject matter is further illustrated
by the following specific but non-limiting examples. The
following examples may include compilations of data that are
representative of data gathered at various times during the
course of development and experimentation related to the
present invention.
Throughout this document, various references are men
tioned. All such references are incorporated herein by refer
ence, including the references set forth in the following list:
REFERENCES

summed as “Non-functional CD33’ to estimate the total
effect of rS444.

Non-functional CD33 was significantly associated with

value. It is also understood that there are a number of values

as “about that particular value in addition to the value itself.
For example, if the value “10 is disclosed, then “about 10” is

shows that Int1-CD33 is also correlated with rS444. This

result steps from the fact that, as shown in Example 1, exon 2
splicing correlates with rS444 genotype.
Using the same methods and materials described in rela
tion to Example 1, an Int1-CD33 specific qPCR assay was
generated (FIG. 5). As shown in FIG. 5, Int1-CD33 expres
sion correlated with total CD33 expression (FIG. 5A,

embodiments +20%, in some embodiments +10%, in some
embodiments +5%, in some embodiments +1%, in some
embodiments +0.5%, and in some embodiments +0.1% from

65

3. Andrews, R. G., J. W. Singer, and I. D. Bernstein, Precur
sors of colony-forming cells in humans can be distin
guished from colony-forming cells by expression of the
CD33 and CD34 antigens and light scatter properties. The
Journal of experimental medicine, 1989. 169(5): p. 1721
31.

4. Bachstetter, A.D. and L. J. Van Eldik. The p38 MAP Kinase
Family as Regulators of Proinflammatory Cytokine Pro
duction in Degenerative Diseases of the CNS. Aging and
disease, 2010. 1(3): p. 199-211.
5. Bachstetter, A. D., B. Xing, L. de Almeida, E. R. Dima
yuga, D. M. Watterson, and L. J. Van Eldik, Microglial
p38alpha MAPK is a key regulator of proinflammatory
cytokine up-regulation induced by toll-like receptor (TLR)
ligands or beta-amyloid (Abeta). Journal of neuroinflam
mation, 2011. 8: p. 79.
6. Bradshaw EM, Chibnik L. B. Keenan BT, Ottoboni L, Raj
T. Tang A. Rosenkrantz LL, Imboywa S. Lee M. Von Korff
A; Alzheimer Disease Neuroimaging I, Morris MC, Evans
DA, Johnson K, Sperling RA, Schneider JA, Bennett DA,
De Jager P L (2013) CD33 Alzheimer's disease locus:
altered monocyte function and amyloid biology. Nat Neu
rosci 16:848-850.

US 9,066,928 B1
15
16
. Brinkman-Van der Linden E. C. Angata T. Reynolds SA,
phy M. P. BACE2 expression increases in human neurode
Powell L D, Hedrick S M, Varki A (2003) CD33/Siglec-3
generative disease. Am. J. Pathol. 180:337-350 (2012).
binding specificity, expression pattern, and consequences 20. Hollingworth P. Harold D. Sims R. Gerrish A. Lambert J
C. Carrasquillo MM. Abraham R. Hamshere ML, Pahwa
of gene deletion in mice. Mol Cell Biol 23:4199-4206.
. Burchett M. E. Ling IF, Estus S. FBN1 isoform expression 5 JS, Moskvina V. Dowzell K, Jones N, Stretton A, Thomas
varies in a tissue and development-specific fashion. Bio
C, Richards A, Ivanov D, Widdowson C, Chapman J, Love
chem Biophys Res Commun. 411: 323-8 (2011).
stone S. Powell J, et al. (2011) Common variants at
9. Delrieu, J., P.J. Ousset, C. Caillaud, and B. Vellas, Clinical
ABCA7, MS4A6A/M S4A4E, EPHA1, CD33 and CD2A
P are associated with Alzheimer's disease. Nat Genet
trials in Alzheimer's disease: immunotherapy approaches.
10
43:429-435.
J. Neurochem., 2012. 120: p. 186-93.
10. Feldman, E. J. J. Brandwein, R. Stone, M. Kalaycio, J. 21. Hsieh, C. L., M. Koike, S. C. Spusta, E. C. Niemi, M.
Moore, J. O'Connor, N. Wedel, G. J. Roboz, C. Miller, R.
Yenari, M. C. Nakamura, and W. E. Seaman. A role for
TREM2 ligands in the phagocytosis of apoptotic neuronal
Chopra, J. C. Jurcic, R. Brown, W. C. Ehmann, P. Schul
man, S. R. Frankel, D. De Angelo, and D. Scheinberg,
cells by microglia. J Neurochem, 2009. 109(4): p. 1144-56.
Phase III randomized multicenter study of a humanized 15 22. Imbimbo, B. P. S. Ottonello, V. Frisardi, V. Solfrizzi, A.
anti-CD33 monoclonal antibody, lintuzumab, in combina
Greco, D. Seripa, A. Pilotto, and F. Panza, Solanezumab for
the treatment of mild-to-moderate Alzheimer's disease.
tion with chemotherapy, versus chemotherapy alone in
patients with refractory or first-relapsed acute myeloid leu
Expert Rev. Clin. Immunol., 2012. 8: p. 135-49.
23. Jandus, C. H. U. Simon, and S. von Gunten, Targeting
kemia. J. Clin. Onc., 2005. 23: p. 4110-6.
siglecs—a novel pharmacological Strategy for immuno
11. Gonzalez, Y., M. T. Herrera, G. Soldevila, L. Garcia
and glycotherapy. Biochemical pharmacology, 2011.
Garcia, G. Fabian, E. M. Perez-Armendariz, K. Bobadilla,
S. Guzman-Beltran, E. Sada, and M. Torres, High glucose
82(4): p. 323-32.
concentrations induce TNF-alpha production through the 24. J Jonsson T. Stefansson H. Steinberg S. Jonsdottir I,
down-regulation of CD33 in primary human monocytes.
Jonsson PV. Snaedal J, Bjornsson S. Huttenlocher J. Levey
25
BMC immunology, 2012. 13: p. 19.
AI, Lah JJ. Rujescu. D. Hampel H. Giegling I. Andreassen
12. Grear, K. E. I. F. Ling, J. F. Simpson, J. L. Furman, C. R.
OA, Engedal K, Ulstein I, Durovic S, Ibrahim-Verbaas C,
Simmons, S. L. Peterson, F. A. Schmitt, W. R. Markesbery,
Hofman A, Ikram M. A. et al. (2013) Variant of TREM2
associated with the risk of Alzheimer's disease. N Engl J
Q. Liu, J. E. Crook, S. G. Younkin, G. Bu, and S. Estus,
Expression of SORL1 and a novel SORLJ splice variant in
Med., 2012, 368: 107-116.
normal and Alzheimers disease brain. Mol Neurodegener, 30 25. Jun G. NajAC, Beecham G. W. Wang LS, Buros J. Gallins
2009. 4: p. 46.
13. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN,
Asselin C N, Mullin K, Hooli B, Choi SH, Hyman BT.
Tanzi R E (2013) Alzheimer's disease risk gene CD33
inhibits microglial uptake of amyloid beta. Neuron 78:631

PJ, Buxbaum J D, Ertekin-Taner N, Fallin MD, Friedland

35

643.

14. Griffin, J. D., D. Linch, K. Sabbath, P. Larcom, and S. F.

Schlossman, A monoclonal antibody reactive with normal
and leukemic human myeloid progenitor cells. Leukemia
research, 1984. 8(4): p. 521-34.
15. Guerreiro R. Wojtas A, Bras J. Carrasquillo M. Rogaeva
E. Majounie E. Cruchaga C, Sassi C, Kauwe J S. Younkin
S. Hazrati L, Collinge J. Pocock J. Lashley T. Williams J.
Lambert J. C. Amouyel P. Goate A. Rademakers R. Morgan
K, et al. (2013) TREM2 variants in Alzheimer's disease. N
Engl J Med 368: 117-127.

40

45

2009. 41: p. 1094-9.
28. Ling IF, Bhongsatiern J. Simpson J. F. Fardo D. W. Estus
S (2012) Genetics of clusterin isoform expression and
50

55

60

31. Liu, Z., C. Condello, A. Schain, R. Harb, and J. Grutzen

17. Harold D, Abraham R. Hollingworth P. Sims R. Gerrish A,
Hamshere ML, Pahwa J S. Moskvina V. DowZell K, Wil

with Alzheimer’s disease. Nat Genet 41:1088-1093.

18. Hernandez-Caselles T. Martínez-Esparza M. Pe'erez
Oliva A B, Quintanilla-Cecconi A M, García-Alonso A,
Alvarez-Lopez, DM, GarcíaPen-arrubia P (2006) A study
of CD33 (SIGLEC-3) antigen expression and function on
activated human Tand NK cells: two isoforms of CD33 are

generated by alternative splicing. J Leukoc Biol 79:46-58.
19. Holler C J, Webb RL, Laux AL, Beckett TL, Niedowicz

DM, Ahmed R R, Liu Y. Simmons C R. Dowling A L,
Spinelli A, Khurgel M, Estus S, Head E. Hersh L B. Mur

Alzheimer’s disease risk. PLoS One 7:e33923.

29. Linnartz, B, Neumann H (2013) Microglial activatory
(immunoreceptor tyrosine-based activation motif)- and
inhibitory (immunoreceptor tyrosine-based inhibition
motif)-signaling receptors for recognition of the neuronal
glycocalyx. Glia 61:37-46.
30. Linnartz B. Wang Y. Neumann H (2010) Microglial
immunoreceptor tyrosine-based activation and inhibition
motifsignaling in neuroinflammation. IntJAlzheimers Dis
2010.pii: 587463.

Alzheimer’s disease. PLoS One 5:e951O.

liams A, Jones N. Thomas C. Stretton A. Morgan A. R.
Lovestone S. Powell J. Proitsi P. Lupton M K. Brayne C,
Rubinsztein DC, et al. (2009) Genome-wide association
study identifies variants at CLU and PICALM associated

p. 243-51.
27. Lambert, J. C. S. Heath, G. Even, D. Campion, K. Slee
gers, M. Hiltunen, O. Combarros, D. Zelenika, et al.,
Genome-wide association study identifies variants at CLU
and CR1 associated with Alzheimer's disease. Nat. Genet.,

16. Guerreiro RJ, Beck J, Gibbs J R Santana I, Rossor MN,

Schott J M, Nalls MA, Ribeiro H, Santiago B, Fox NC,
Oliveira C, Collinge J. Mead S. Singleton A, Hardy J
(2010) Genetic variability in CLU and its association with

R, Inzelberg R, Kramer P. Rogaeva E. St George-Hyslop P.
St George-Hyslop P. Cantwell L. B. Dombroski B. A.
Saykin AJ, Reiman EM, Bennett DA, et al. (2010) Meta
analysis confirms CR1, CLU, and PICALM as alzheimer
disease risk loci and reveals interactions with APOE geno
types. Arch Neurol 67:1473-1484.
26. Lajaunias, F. J. M. Dayer, and C. Chizzolini, Constitutive
repressor activity of CD33 on human monocytes requires
sialic acid recognition and phosphoinositide 3-kinase-me
diated intracellular signaling. Euro. J. Immunol., 2005.35:

65

dler, CX3CR1 in microglia regulates brain amyloid depo
sition through selective protofibrillar amyloid-beta phago
cytosis. The Journal of neuroscience: the official journal of
the Society for Neuroscience, 2010.30(50): p. 17091-101.
32. Morgan, D., D.M. Diamond, P. E. Gottschall, K.E. Ugen,
C. Dickey, J. Hardy, K. Duff, P. Jantzen, G. DiCarlo, D.
Wilcock, K. Connor, J. Hatcher, C. Hope, M. Gordon, and

US 9,066,928 B1
17
G. W. Arendash. A beta peptide vaccination prevents
memory loss in an animal model of Alzheimer's disease.
Nature, 2000. 408: p. 982-5.
33. Morgan K (2011) The three new pathways leading to
Alzheimer's disease. Neuropathol ApplNeurobiol37:353

5

357.

34. Naj AC, Jun G. Beecham G. W. Wang L S. Vardarajan B

18
44. Smith, J. D., Moylan, J. S., Hardin, B.J., Chambers, M.
A., Estus, S., Telling, G. C., Reid, M. B. Prion protein
expression and functional importance in skeletal muscle.
Antioxid Redox Signal. 15: 2465-75 (2011).
45. Smith PJ, Zhang C. Wang J, Chew S. L. Zhang M Q.
Krainer A R (2006) An increased specificity score matrix
for the prediction of S F2/ASF-specific exonic splicing
enhancers. Hum Mol Genet 15:2490-2508.

N, Buros J. Gallins PJ, Buxbaum J D, Jarvik G. P. Crane P
K, Larson E B, Bird TD, Boeve B F, Graff-Radford NR,
variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1

46. Stasi, R., Gemtuzumab ozogamicin: an anti-CD33 immu
noconjugate for the treatment of acute myeloid leukaemia.
Expert Opin. Biol. Then, 2008. 8: p. 527–40.
47. Sutherland, M. K. C. Yu, T. S. Lewis, J. B. Miyamoto, C.

are associated with lateonset Alzheimer's disease. Nat
Genet 43:436-441.

A. Morris-Tilden, M. Jonas, J. Sutherland, A. Nesterova,
H. P. Gerber, E. L. Sievers, I. S. Grewal, and C. L. Law,

De Jager P L., Evans D, Schneider JA, Carrasquillo MM.
Ertekin-Taner N. Younkin SG, et al. (2011) Common
35. Nelson PT, Braak H. Markesbery W R (2009) Neuropa
thology and cognitive impairment in Alzheimer disease: a
complex but coherent relationship. J Neuropathol Exp

10

15

Neurol 68:1-14.

36. Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo D
W. Estus S, Rebeck G. W. APOE-E2 and APOE-E4 Corre

late With Increased Amyloid Accumulation in Cerebral
Vasculature. J Neuropathol Exp Neurol. 72:708-15 (2013).
37. Neumann H, Daly MJ (2013) Variant TREM2 as risk
factor for Alzheimer's disease. NEnglJMed 368:182-184.
38. Perez-Oliva A B, Martinez-Esparza M, Vicente
Fernandez J.J. Corral-San Miguel R. García-Penarrubia P.
Hernandez-Caselles T (2011) Epitope mapping, expres
sion and post-translational modifications of two isoforms
of CD33 (CD33M and CD33m) on lymphoid and myeloid
human cells. Glycobiology 21:757-770.
39. Raza, A.J. G. Jurcic, G.J. Roboz, M. Maris, J.J. Stephen
son, B. L. Wood, E.J. Feldman, N. Galili, L. E. Grove, J. G.
Drachman, and E. L. Sievers, Complete remissions
observed in acute myeloid leukemia following prolonged
exposure to lintuZumab: a phase 1 trial. Leuk. & Lymph.
2009. 50: p. 1336-44.
40. Scheinberg, D. A. D. Lovett, C. R. Divgi, M. C. Graham,

KLYu C, Poon WW, Cornwell LB, Miller CA, Vinters H

25

30

40

45

SEQUENCE LISTING

<16 Os NUMBER OF SEO ID NOS : 18
<21 Os SEQ ID NO 1
&211s LENGTH: 18
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence

52. Youmans KL, Tai L. M. Nwabulisi-Heath E. Jungbauer L.
Kanekiyo T. Gan M. Kim J. Eimer WA, Estus S, Rebeck G.
W. Weeber E. J. Bu G, Yu C, Ladu MJ. APOE4-specific
changes in AB accumulation in a new transgenic model of
Alzheimer's Disease. J Biol Chem. 287:41774-86 (2012).
53. Zhu, H., H. M. Tucker, K. E. Grear, J. F. Simpson, A. K.
Manning, L.A. Cupples, and S. Estus. A common polymor
phism decreases low-density lipoprotein receptor exon 12
splicing efficiency and associates with increased choles
terol. Hum Mol Genet, 2007. 16(14): p. 1765-72.
54. Zou F, Gopalraj RK Lok J, Zhu H. Ling IF, Simpson JF,
Tucker H M. Kelly J. F. Younkin S G, Dickson D. W.
Petersen RC, Graff-Radford N.R, Bennett DA, Crook JE,

50

Estus S (2008) Sex-dependent association of a common
lowdensity lipoprotein receptor polymorphism with RNA
splicing efficiency in the brain and Alzheimer's disease.
Hum Mol Genet 17:929-935.

43. Simmons CR, Zou F. Younkin SG, Estus S. Rheumatoid

arthritis-associated polymorphisms are not protective
against Alzheimer's disease. Mol Neurodegener. 6:33
(2011).

50. Vasquez, JB, Fardo, DW and Estus, S.ABCA7 expres
sion is associated with Alzheimer's disease polymorphism
and disease status. Neurosci. Lett. In Press (2013).
51. Visconte V. Makishima H. Maciejewski J. P. Tiu RV
(2012) Emerging roles of the spliceosomal machinery in
myelodysplastic syndromes and other hematological dis
orders. Leukemia 26:2447-2454.

35

42. Simmons CR, Zou F. Younkin S, Estus S. Evaluation of

the global association between cholesterol-associated
polymorphisms and Alzheimer's disease Suggests a role
for rs3846.662 and HMGCR splicing in disease risk. Mol
Neurodegener. 6:62 (2011).

V. Van Eldik U, Fardo DW. Estus S. Bu G, Gylys KH, Ladu
MJ. Levels of soluble apolipoprotein E/amyloid-fi com
plex are reduced and oligomeric A? increased with APOE4
and Alzheimer disease in a transgenic mouse model and
human samples. J Biol Chem. 2013 288:5914-26 (2013).
49. Varki A, Angata T (2006) Siglecs—the major subfamily of
I-type lectins. Glycobiology 16:1R-27R. CrossRef Med
line

E. Berman, K. Pentlow, N. Feirt, R. D. Finn, B. D. Clark

son, T. S. Gee, and et al. A phase I trial of monoclonal
antibody M195 in acute myelogenous leukemia: specific
bone marrow targeting and internalization of radionuclide.
J. Clin. Onc., 1991.9: p. 478-90.
41. Sgouros, G., M. C. Graham, C. R. Divgi, S. M. Larson,
and D. A. Scheinberg, Modeling and dosimetry of mono
clonal antibody M195 (anti-CD33) in acute myelogenous
leukemia. Journal of nuclear medicine: official publication,
Society of Nuclear Medicine, 1993. 34(3): p. 422-30.

Anti-leukemic activity of lintuzumab (SGN-33) in pre
clinical models of acute myeloid leukemia. mAbs, 2009. 1:
p. 481-90.
48. Tai LM, Bilousova T. Jungbauer L. Roeske S K, Youmans

55

It will be understood that various details of the presently
disclosed subject matter can be changed without departing
from the scope of the subject matter disclosed herein. Fur
thermore, the foregoing description is for the purpose of
illustration only, and not for the purpose of limitation.
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20
- Continued

22 Os. FEATURE:

223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 1

citcaga catg cc.gctgct

18

<210s, SEQ ID NO 2
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 2

ttcaatggcc atcatctoct
<210s, SEQ ID NO 3
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 3

catcc catga aagttgaggg
<210s, SEQ ID NO 4
&211s LENGTH: 18
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
& 22 O FEATURE;
223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 4

tactgctgcc cct gctgt
<210s, SEQ ID NO 5
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 5

tggc catcat citcctgat ct
<210s, SEQ ID NO 6
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 6

aatgcagotc ct catc catc
<210s, SEQ ID NO 7
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

223s OTHER INFORMATION: Primer

<4 OO > SEQUENCE: 7

tgttccacag aacccaacaa

18
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22
- Continued

<210s, SEQ ID NO 8
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 8

ggctgtaa.ca cca.gct cotc
<210s, SEQ ID NO 9
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 9

CCCtgctgtg ggcagacittg
<210s, SEQ ID NO 10
&211s LENGTH: 21
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 10

gCaccgagga gtgagtag to c
<210

SEQ ID NO 11

&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 11

ctgtgc.ccga gctgtctitat
<210s, SEQ ID NO 12
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 12

aggctic ctitc ctacctgagc
<210s, SEQ ID NO 13
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

223s OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 13

gctgccacct tcactttacc
<210s, SEQ ID NO 14
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

223s OTHER INFORMATION: Primer

21
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23
- Continued
<4 OOs, SEQUENCE: 14

ttgttgggitt Ctgtggaa.ca
SEO ID NO 15
LENGTH: 22
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Primer
< 4 OOs

SEQUENCE: 15

cagotcaacg to acctatgt to

22

SEQ ID NO 16
LENGTH: 2O
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 16

cgtagaatcg agaccgagga
SEO ID NO 17
LENGTH: 23
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Primer
< 4 OO

SEQUENCE: 17

tgct tactgg cittatcgaaa tta

23

SEQ ID NO 18
LENGTH: 18
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Primer

<4 OOs, SEQUENCE: 18

tgtgggtcaa gtctgc cc

18

45

What is claimed is:

1. A method of treating Alzheimer's disease in a Subject,
comprising:
administering a CD33 antibody to the subject, the subject
being identified as having a single nucleotide polymor
phism (SNP) selected from rs3865444, rs12459419, and

4. The method of claim 3, wherein the at least one addi

tional component useful for treating Alzheimer's disease is
selected from galantamine, rivastigmine, donepezil, tacrine,
50

5. The method of claim 1, wherein the subject is not being

combinations thereof.

treated for a cancer.

2. The method of claim 1, wherein the CD33 antibody
includes lintuzumab, P67.6, or combinations thereof.

3. The method of claim 1, further comprising administer
ing to the Subject at least one additional component useful for
treating Alzheimer's disease.

memantine, Vitamin E, and combinations thereof.

55

6. The method of claim 1, wherein the subject does not have
acute myeloid leukemia (AML) and/or has not been identified
as being at risk for developing AML.
k

k

k

k

k

